<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472326</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-442-4148</org_study_id>
    <nct_id>NCT03472326</nct_id>
  </id_info>
  <brief_title>Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the short-term antiviral potency of
      GS-9131 compared to placebo-to-match (PTM) GS-9131, each administered once daily with the
      existing failing antiretroviral (ARV) regimen.

      This is a two-part study. Part 1 consists of three cohorts: 2 Sentinel Cohorts and 1
      Randomized Cohort. Eligible participants from Part 1 will proceed to Part 2 followed by an
      optional open-label extension.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    GS-9131 did not meet the targeted antiviral response
  </why_stopped>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Actual">December 9, 2019</completion_date>
  <primary_completion_date type="Actual">December 9, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With Plasma HIV-1 RNA Decrease From Baseline Exceeding 0.5 log10 (copies/mL) at Day 15 in the Randomized Cohort in Part 1</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma log10 HIV-1 RNA (copies/mL) at Day 11 for Sentinel Cohort 1 and Day 15 for Sentinel Cohort 2 and the Randomized Cohort in Part 1</measure>
    <time_frame>Baseline to Day 11 and Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Plasma HIV-1 &lt; 0.5 log10 (copies/mL) at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NRTI) Mutations at the time of Virologic Failure</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Protease Inhibitor (PI) Mutations at the time of Virologic Failure</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Integrase Strand-Transfer Inhibitor (INSTI) Mutations at the time of Virologic Failure</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Part 1: Sentinel Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment experienced participants will receive open label GS-9131 60 mg (2 x 30 mg tablets) once daily + current failing antiretroviral therapy (ART) regimen for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Sentinel Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment experienced participants will receive open-label GS-9131 180 mg (6 x 30 mg tablets) once daily + current failing ART for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Cohort (Treatment Arm A: GS-9131)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9131 up to 180 mg once daily + current failing ART regimen for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm B: GS-9131)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9131 up to 180 mg once daily + current failing ART regimen for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm C: GS-9131)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9131 up to 180 mg once daily + current failing ART regimen for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm D: GS-9131 Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9131 placebo + current failing ART regimen for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: GS-9131 60 mg + BIC + DRV + RTV Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Treatment Sentinel Cohort 1 in Part 1 will receive GS-9131 60 mg (2 x 30 mg tablet) + bictegravir (BIC) + darunavir (DRV) + ritonavir (RTV) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: GS-9131 up to 180 mg + BIC + TAF Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Sentinel Cohort 2 and Randomized Cohort (A-D) in Part 1 will receive GS-9131 up to 180 mg + BIC + TAF for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label Extension Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 2 may have the option to receive open-label GS-9131 + BIC + TAF for an additional 24 weeks or until the product becomes accessible to participants through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9131</intervention_name>
    <description>Tablet(s) administered orally once daily. Dose for the open-label extension will be determined following review of the safety, efficacy and available PK data of the Randomized Cohort in Part 1 from Part 2.</description>
    <arm_group_label>Open-label Extension Phase</arm_group_label>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm B: GS-9131)</arm_group_label>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm C: GS-9131)</arm_group_label>
    <arm_group_label>Part 1: Sentinel Cohort 1</arm_group_label>
    <arm_group_label>Part 1: Sentinel Cohort 2</arm_group_label>
    <arm_group_label>Part 2: GS-9131 60 mg + BIC + DRV + RTV Regimen</arm_group_label>
    <arm_group_label>Part 2: GS-9131 up to 180 mg + BIC + TAF Regimen</arm_group_label>
    <arm_group_label>Randomized Cohort (Treatment Arm A: GS-9131)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo-to-match (PTM) GS-9131 tablets</description>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm D: GS-9131 Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIC</intervention_name>
    <description>30 mg tablet(s) administered orally once daily</description>
    <arm_group_label>Open-label Extension Phase</arm_group_label>
    <arm_group_label>Part 2: GS-9131 60 mg + BIC + DRV + RTV Regimen</arm_group_label>
    <arm_group_label>Part 2: GS-9131 up to 180 mg + BIC + TAF Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAF</intervention_name>
    <description>25 mg tablet(s) administered orally once daily</description>
    <arm_group_label>Open-label Extension Phase</arm_group_label>
    <arm_group_label>Part 2: GS-9131 up to 180 mg + BIC + TAF Regimen</arm_group_label>
    <other_name>VemlidyÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART regimen</intervention_name>
    <description>ART regimen may consist of the current failing antiretroviral agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)</description>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm B: GS-9131)</arm_group_label>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm C: GS-9131)</arm_group_label>
    <arm_group_label>Part 1: Randomized Cohort (Treatment Arm D: GS-9131 Placebo)</arm_group_label>
    <arm_group_label>Part 1: Sentinel Cohort 1</arm_group_label>
    <arm_group_label>Part 1: Sentinel Cohort 2</arm_group_label>
    <arm_group_label>Randomized Cohort (Treatment Arm A: GS-9131)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRV</intervention_name>
    <description>800 mg tablet(s) administered orally once daily</description>
    <arm_group_label>Part 2: GS-9131 60 mg + BIC + DRV + RTV Regimen</arm_group_label>
    <other_name>PrezistaÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTV</intervention_name>
    <description>100 mg tablet(s) administered orally once daily</description>
    <arm_group_label>Part 2: GS-9131 60 mg + BIC + DRV + RTV Regimen</arm_group_label>
    <other_name>NorvirÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Plasma HIV-1 RNA â¥ 500 copies/mL at Screening Visit

          -  Currently taking a failing antiretroviral (ARV) regimen that contains 2 NRTIs and a
             non-NRTI (NNRTI)

          -  No prior or current ARV regimens containing integrase inhibitor (INSTI) or protease
             inhibitor (PI)

          -  Screening genotype must show at least the protocol defined resistance mutation profile

        Key Exclusion Criteria:

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic or antifungal therapy within 30 days prior to Day 1

          -  Participation in any other clinical trial, including observational studies, without
             prior approval from the sponsor is prohibited while participating in this trial

          -  Use of an investigational drug other than the study drug

          -  Individuals with chronic hepatitis B virus (HBV) infection are not permitted to
             participate

          -  Active tuberculosis infection

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joint Clinical Research Centre</name>
      <address>
        <city>Kampala</city>
        <zip>10005</zip>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Research Ethics Committee for the University of Zimbabwe College of Health Sciences and Parirenyatwa Group of Hospitals</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
    <country>Zimbabwe</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

